Kenneth Mills will become chair of the gene therapy developer’s board. Curran Simpson, the current chief operating officer, will take his place as company head.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,